CD8A and asthma: This review has framed asthma heterogeneity through T-cell axes—Th2/ILC2, Th17/Treg, Tfh/Breg, and CD8+ programs—and then mapped approved and investigational therapies onto those pathways (4, 7, 17–34, 36–43).Read together, Sections 2 and 3 indicate a simple organizing principle: when disease biology is dominated by a single axis (e.g., eosinophilic or allergic type-2), axis-matched biologics deliver the most reliable benefit; when signals are mixed or weak, upstream epithelial cues (e.